Close Menu

marketing agreement

The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.

Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

The deals cover Plexbio's IntelliPlex 1000 πCode Processor and the PlexBio 100 Fluorescent Analyzer for the IVD and life science research markets.

The five CROs will be able to offer DSP analyses to their customers through a technology access program ahead of NanoString's planned platform launch in 2019.

The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy. 

Thermo Fisher will sell Synthego's synthetic guide RNA products under the Invitrogen TrueGuide brand. 

The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.

Pages

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.